Precision BioSciences Announces Changes to Senior Leadership Team to Support Advancement of Programs Through Next Set of Clinical Milestones
Precision BioSciences Inc DTIL
$6.99
▼ -0.14%
($-0.01)
📅 Earnings This Week
Open
$7.08
Prev Close
$7.00
Day Range
$6.76 – $7.21
52W Range
$3.53 – $9.62
Market Cap
$180.36M
Beta
1.28
EPS (TTM)
$-3.67
📋 Company Profile
| Industry | Biotechnology |
| Country | US |
| Exchange | NASDAQ NMS - GLOBAL MARKET |
| Currency | USD |
| IPO Date | 2019-03-28 |
| Shares Out. | 25,800,000 |
| Website | precisionbiosciences.com/ ↗ |
| Phone | 13026587581 |
| Employees | 66 |
| Revenue | $10.8M |
| Gross Profit | $10.8M |
| Net Income | -$18.4M |
| Free Cash Flow | -$58.8M |
| Total Assets | $143.9M |
| Total Liabilities | $67.8M |
| Equity | $76.1M |
About Precision BioSciences Inc
Precision BioSciences Inc clinical stage gene editing company utilizing its proprietary ARCUS platform to concurrently develop two clinical-stage in vivo gene editing therapies. The ARCUS platform is used to develop in vivo gene editing therapies for sophisticated gene edits, including gene insertion (inserting DNA into gene to cause expression/add function), elimination (removing a genome, e.g. viral DNA), and excision (removing a large portion of a defective gene by delivering two ARCUS nucleases in a single adeno-associated virus ("AAV")).
Precision BioSciences Inc is a publicly traded company under the ticker symbol DTIL on the NASDAQ NMS - GLOBAL MARKET, operating in the Biotechnology industry. Quotes and metrics shown here are sourced from public market data and refreshed regularly.
📊 Analyst Ratings
11 analysts (2026-07-01)